CDC42 and EZH2 are overexpressed in colorectal cancer: Are they minimal invasive diagnostic markers? Minimal invasive diagnostic markers for CRC

Tuba Denkçeken; Elif Onur; Mehmet Şahin; Rabia Milli

doi:10.28982/josam.8069

Authors

Tuba Denkçeken SANKO University, Faculty of Medicine, Department of Biophysics, Gaziantep, Turkey https://orcid.org/0000-0002-4663-5410
Elif Onur SANKO University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey https://orcid.org/0000-0002-1690-3170
Mehmet Şahin Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey https://orcid.org/0000-0001-8312-5156
Rabia Milli Gaziantep University, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey https://orcid.org/0000-0003-0246-0687

DOI:

https://doi.org/10.28982/josam.8069

Keywords:

Colorectal Cancer, CDC42, EZH2, noninvasive biomarker

Abstract

Background/Aim: Bioinformatics methods have been used to show that cell division cycle 42 (CDC42) and enhancer of zeste homolog 2 (EZH2) have potential oncogenic effects in colorectal cancer (CRC). In this study, we performed experimental validation of these genes.

Methods: We considered the possible role of CDC42 and EZH2 genes in SW480 and SW620 cells. Furthermore, blood samples were gathered from CRC patients and healthy controls to compare CDC42 and EZH2 levels, and relative mRNA and protein levels were measured.

Results: CDC42 and EZH2 expression levels were significantly increased in the SW480 and SW620 cell lines when compared with normal CRL-1790. In addition, when we examined CDC42 and EZH2 expression levels in blood samples of 20 CRC patients and 20 healthy controls by RT-qPCR, the levels of CDC42 and EZH2 were significantly upregulated in patients with CRC compared with healthy control subjects. Similar results were obtained in terms of the protein expression levels of CDC42 and EZH2.

Conclusion: These data reveal that CDC42 and EZH2 are significantly overexpressed in CRC. Considering that high gene and protein expression levels of CDC42 and EZH2 were found in the serum of patients suffering from CRC, these two genes may be developed as minimally invasive diagnostic markers for CRC detection.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Rasool S, Kadla SA, Rasool V, Ganai BA. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumor biol. 2013;34(5):2469-76.

Slattery ML, Herrick JS, Mullany LE, Samowitz WS, Sevens JR, Sakoda L, et al. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. Genes Chromosomes Cancer. 2017;56(11):769-87.

Onur E, Denkçeken T. Integrative analysis of molecular genetic targets and pathways in colorectal cancer through screening large-scale microarray data. Int J Data Min Bioin. 2021;26(1-2):81-98.

Braga VM, Yap AS. The challenges of abundance: epithelial junctions and small GTPase signalling. Curr Opin Cell Biol. 2005;17(5):466-74.

Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005;27(6):602-13.

Gómez Del Pulgar T, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, et al. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol. 2008;33(1):185-93.

Sakamori R, Yu S, Zhang X, Hoffman A, Sun J, Das S, et al. CDC42 inhibition suppresses progression of incipient intestinal tumors. Cancer Res. 2014;74(19):5480-92.

van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol. 2007;52(2):455-63.

Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol. 2011;38(2):345-53.

He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, et al. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev. 2012;13(7):3173-8.

Huqun, Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer. 2012;118(6):1599-606.

Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2009;28(6):843-53.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185-97.

Ferraro A, Mourtzoukou D, Kosmidou V, Avlonitis S, Kontogeorgos G, Zografos G, et al. EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells. Int J Biochem Cell Biol. 2013;45(2):243-54.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.

Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174.

Qadir MI, Parveen A, Ali M. Cdc42: Role in Cancer Management. Chem Biol Drug Des. 2015;86(4):432-9.

Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y, et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res. 2004;10(14):4799-805.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24(2):268-73.

Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2020;156(2):423-9.

Valdés-Mora F, Locke WJ, Bandrés E, Gallego-Ortega D, Cejas P, García-Cabezas MA, Colino-Sanguino Y, Feliú J, Del Pulgar TG, Lacal JC. Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. Oncotarget. 2017;8(16):26755-70.

Chen JF, Luo X, Xiang LS, Li HT, Zha L, Li N, He JM, Xie GF, Xie X, Liang HJ. EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling. Oncotarget. 2016;7(27):41540-58.

Chen Z, Yang P, Li W, He F, Wei J, Zhang T, Zhong J, Chen H, Cao J. Expression of EZH2 is associated with poor outcome in colorectal cancer. Oncol Lett. 2018;15(3):2953-61.

Li Y, Sun Z, Liu B, Shan Y, Zhao L, Jia L. Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer. Cell Death Dis. 2017;8(6):e2892.

Si Z, Yu L, Jing H, Wu L, Wang X. Oncogenic lncRNA ZNF561-AS1 is essential for colorectal cancer proliferation and survival through regulation of miR-26a-3p/miR-128-5p-SRSF6 axis. J Exp Clin Cancer Res. 2021;40(1):78.

Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One. 2011;6(7):e21651.

Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H. Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer. Oncol Lett. 2018;16(4):5275-81.

Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, Hommes DW, Offerhaus GJ, van den Brink GR, Hardwick JC. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis. 2010;31(9):1567-75.

Gao S, Xue J, Wu X, Zhong T, Zhang Y, Li S. The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients. J Clin Lab Anal. 2022;36(7):e24572.